BioCryst Completes $700 Million Acquisition of Astria Therapeutics to Strengthen Hereditary Angioedema Leadership
核心洞察
BioCryst Pharmaceuticals completed its $700 million acquisition of Astria Therapeutics (搜索) on January 23, 2026, adding the late-stage plasma kallikrein (搜索) inhibitor navenibart to its hereditary angioedema (搜索) portfolio.
Navenibart, currently in Phase 3 development, has the potential to become the first HAE therapy with every-three and every-six month dosing intervals, offering significant treatment convenience improvements.
The acquisition positions BioCryst to offer both the leading oral therapy ORLADEYO and a potentially best-in-class injectable prophylactic option for individualized HAE patient care.
BioCryst Pharmaceuticals completed its acquisition of Astria Therapeutics (搜索) on January 23, 2026, for an implied transaction value of approximately $700 million, net of Astria's cash at closing. The strategic acquisition strengthens BioCryst's position as a leader in hereditary angioedema (搜索) (HAE) treatment and enhances the company's long-term growth trajectory.
Expanding HAE Portfolio with Late-Stage Asset
The acquisition adds navenibart, a late-stage, long-acting plasma kallikrein (搜索) inhibitor currently in Phase 3 clinical development, to BioCryst's HAE portfolio. Navenibart has the potential to be the first HAE therapy with every-three and every-six month dosing intervals, combined with a high level of attack control, which could significantly improve the treatment experience for HAE patients.
With the addition of navenibart, BioCryst could offer both the leading oral therapy ORLADEYO (berotralstat) and a potentially best-in-class injectable prophylactic option, empowering physicians and patients with optimal choices for individualized care. BioCryst expects its commercial infrastructure, patient support platform, and deep HAE expertise will maximize the launch trajectory and peak revenue potential of navenibart with minimal incremental commercial investment.
Transaction Structure and Financing
BioCryst financed the cash portion of the acquisition with cash on hand and approximately $396.6 million (net of expenses) drawn from a financing facility with funds managed by Blackstone (搜索). At the closing of the transaction, BioCryst issued approximately 37.3 million shares of its common stock to Astria's equity holders.
The acquisition was approved by Astria stockholders at a special meeting held on January 21, 2026, with the transaction closing two days later as expected.
Leadership Integration and Additional Assets
Jill C. Milne, Ph.D., Co-Founder and Chief Executive Officer of Astria Therapeutics (搜索), has joined the BioCryst Board of Directors, further strengthening the company's strategic leadership and rare disease expertise. Additionally, John Ruesch, Senior Vice President, Pharmaceutical Sciences and Technical Operations at Astria, has joined BioCryst as Chief Technical Operations Officer, bringing deep CMC and product development expertise to support the advancement and commercialization of navenibart and other pipeline programs.
BioCryst also obtained Astria's early-stage program for atopic dermatitis (搜索), STAR0310, for which the company plans to pursue strategic alternatives.
Strategic Positioning in Rare Disease Market
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (搜索) and other rare diseases. The company has commercialized ORLADEYO, the first oral, once-daily plasma kallikrein (搜索) inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases.
The transaction was advised by BofA Securities, Inc. as exclusive financial advisor and Covington & Burling LLP as legal counsel to BioCryst, while Evercore served as exclusive financial advisor and Sidley Austin LLP served as legal counsel to Astria.